Neck Cancer

Individuals with cannabis-related disorder exhibited increased risk for head and neck cancer, results of a retrospective cohort study showed.

The addition of setanaxib to pembrolizumab in adults with squamous cell carcinoma of the head and neck conferred significant improvement in both PFS and OS, according to a topline data release from the agent’s manufacturer.

White patients and those with nonoropharyngeal cancer and advanced disease appeared more likely to receive immunotherapy for head and neck cancer squamous cell carcinoma, according to study results.

Better oral health appeared associated with higher survival rates among individuals diagnosed with head and neck cancer, results published in Journal of the National Cancer Institute showed.

Approximately 15% of individuals with head and neck cancer received an antibiotic prescription within 3 months of diagnosis, study results showed.

BMI in the overweight range appeared independently associated with favorable outcomes among patients who underwent chemoradiotherapy for nonmetastatic head and neck cancer, according to study results published in JAMA Network Open.

Stereotactic body radiation therapy combined with single-dose durvalumab before surgery appeared safe and induced durable responses among patients with HPV-unrelated locally advanced head and neck cancer, according to study results.

Research in 2022 spotlighted several innovative and potentially effective treatment regimens for head and neck cancer.

Certain factors may help predict which patients treated for head and neck cancer will require long-term gastrostomy tube use, according to study results.

The FDA granted priority review to cabozantinib for treatment of certain patients with differentiated thyroid cancer.